In mul­ti­ple myelo­ma show­down, J&J adds an­oth­er feath­er to Darza­lex's cap

Sanofi’s Sar­clisa burst on­to the mul­ti­ple myelo­ma scene last year to chal­lenge J&J’s CD38 heavy­weight Darza­lex. But J&J isn’t go­ing down with­out a fight, and now it’s tout­ing an­oth­er ap­proval for the hard-to-treat blood can­cer — along with an eas­i­er route of ad­min­is­tra­tion that could save pa­tients hours of their time.

The FDA has giv­en Darza­lex Faspro the thumbs-up as a sec­ond-line treat­ment for adults with mul­ti­ple myelo­ma in com­bi­na­tion with po­ma­lido­mide and dex­am­etha­sone (Pd), Janssen said Mon­day. The ap­proval marks the sixth in­di­ca­tion for Darza­lex Faspro, which is co-for­mu­lat­ed with Halozyme’s re­com­bi­nant hu­man hyaluronidase PH20, a type of en­zyme that cat­alyzes the degra­da­tion of hyaluron­ic acid.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER